Summary
In general, tumors induce angiogenic factors specific to them, which leads to angiogenesis with advancement. However, angiogenesis in uterine endometrial cancers is complicated because hormone dependency in growth also modifies the angiogenic potential. Therefore, tumor-dormancy therapy against angiogenic potential in uterine endometrial cancers must be thoroughly considered. Upstream of the vascular endothelial growth factor (VEGF) gene conserves estrogen-responsive elements. Progesterone primed with estrogen induces thymidine phosphorylase (TP) in uterine endometrium. Sex steroid-dependent VEGF and TP are highly expressed in cases of early stage and well-differentiated uterine endometrial cancers, as is basic fibroblast growth factor (bFGF) in cases of advanced and poorly differentiated uterine endometrial cancers. A transcriptional factor for angiogenesis, namely ETS-1, is linked to VEGF in well-differentiated uterine endometrial cancers and to bFGF in poorly differentiated uterine endometrial cancers. Therefore, even if dedifferentiation and angiogenic switching occur due to advancement and long-term hormone therapy, the inhibition of ETS-1, along with main angiogenic factors, may be an effective strategy to suppress uterine endometrial cancers as a novel tumor-dormancy therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175–203
Fujimoto J, Ichigo S, Hori M et al. (1997) Expression of basic fibroblast growth factor and its mRNA in advanced uterine cervical cancers. Cancer Lett 111:21–26
Fujimoto J, Hori M, Ichigo S et al. (1995) Expression of basic fibroblast growth factor and its mRNA in uterine endometrial cancers. Invasion Metastasis 15:203–210
Fujimoto J, Ichigo S, Sakaguchi H et al. (1999) The expression of platelet-derived endothelial cell growth factor in uterine cervical cancers. Br J Cancer 79:1249–1254
Fujimoto J, Sakaguchi H, Hirose R et al. (1999) Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers. Cancer Res 59:3041–3044
Fujimoto J, Sakaguchi H, Aoki I et al. (2000) The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers. Cancer Res 60:3662–3665
Fujimoto J, Ichigo S, Sakaguchi H et al. (1998) Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers. Cancer Lett 130:115–120
Fujimoto J, Sakaguchi H, Hirose R et al. (1999) Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer 80:827–833
Fujimoto J, Ichigo S, Hirose R et al. (1998) Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. Cancer Lett 134:15–22
Fujimoto J, Sakaguchi H, Aoki I et al. (2000) Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res 60: 2632–2635
Fujimoto J, Aoki I, Khatun S et al. (2002) Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cervical cancers. Ann Oncol 13:430–434
Fujimoto J, Ichigo S, Sakaguchi H et al. (1998) Expression of platelet-derived endothelial cell growth factor in uterine endometrium during the menstrual cycle. Mol Hum Reprod 4:509–513
Fujimoto J, Sakaguchi H, Hirose R et al. (1999) Progestins suppress estrogen-induced expression of vascular endothelial growth factor (VEGF) subtypes in uterine endometrial cancer cells. Cancer Lett 141:63–71
Fujimoto J, Aoki I, Toyoki S et al. (2003) Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers. Ann Oncol 13:1598–1604
Fujimoto J, Aoki I, Toyoki S et al. (2003) Clinical implications of expression of ETS-1 related to angiogenesis in uterine endometrial cancers. Ann Oncol 13:1605–1611
Fujimoto J, Hori M, Ichigo S et al. (1997) Plausible novel therapeutic strategy of uterine endometrial cancer with reduction of basic fibroblast growth factor secretion by progestin and O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Lett 113:187–194
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Japan
About this chapter
Cite this chapter
Fujimoto, J., Aoki, I., Toyoki, H., Khatun, S., Sato, E., Tamaya, T. (2003). Sex Steroid-Dependent and -Independent Angiogenesis in Uterine Endometrial Cancers. In: Kuramoto, H., Nishida, M. (eds) Cell and Molecular Biology of Endometrial Carcinoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-53981-0_11
Download citation
DOI: https://doi.org/10.1007/978-4-431-53981-0_11
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-67977-6
Online ISBN: 978-4-431-53981-0
eBook Packages: Springer Book Archive